Regulatory Approval

    IVAX Corporation, Miami
David Malina, 305-575-6043
Director/Investor Relations & Corporate Communications

        IVAX Receives Tentative Approval For Topiramate Tablets

IVAX Corporation (AMEX:IVX)(LSE:IVX.L) announced today that it
received tentative approval from the FDA for its Abbreviated New Drug
Application (ANDA) for Topiramate tablets in 25 mg, 100 mg and 200 mg
strengths. Upon final approval, this product will be sold through the
company's wholly owned subsidiary, IVAX Pharmaceuticals, Inc.
Topiramate is the generic equivalent of Topamax(R), which is marketed
by Ortho-McNeil as an anti-epileptic drug to control both partial and
grand mal seizures. U.S. sales of Topamax tablets in the 25, 100 and
200 mg dosage strengths were over $785 million for the past twelve
month ending in the second quarter of 2003.

IVAX continues its aggressive program to increase the number of
products in its generic portfolio.

IVAX Corporation, headquartered in Miami, Florida, discovers,
develops, manufactures, and markets branded and brand equivalent
(generic) pharmaceuticals and veterinary products in the U.S. and
internationally.

Copies of this and other news releases may be obtained free of charge
from IVAX' website at http://www.ivax.com.

The "FDA" refers to the United States Food and Drug Administration.

Except for the historical matters contained herein, statements in this
press release are forward-looking and are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act of
1995. Investors are cautioned that forward-looking statements
including the risks that final approval of IVAX' ANDA for topiramate
tablets in 25 mg, 100 mg and 200 mg strengths may be delayed or not
received at all; that launch of the tablets may be delayed; changing
market conditions; the availability and cost of raw materials and
other third party products; the impact of competitive products and
pricing; that IVAX may not file any additional ANDAs; and other risks
and uncertainties based on economic, competitive, governmental,
technological and other factors discussed in the Company's Annual
Report on Form 10-K and its other filings with the Securities and
Exchange Commission. Topamax(R) is a registered trademark of
Ortho-McNeil.